CompletedPhase 2

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients

263 participantsStarted 2008-11

Plain-language summary

The purpose of this study is to determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with non-proliferative diabetic retinopathy (mild, moderate or severe) and planned cataract extraction by phacoemulsification. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Central subfiled macular thickness greater than or equal to 250 microns * CME in either eye. * Other protocol-defined exclusion criteria may apply.

What they're measuring

Percent of Patients Who Developed Macular Edema (ME) Within 90 Days Following Cataract Surgery

Timeframe: 3 Months

Trial details

NCT IDNCT00782717

SponsorAlcon Research

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-07

Results submitted2011-08-17

View on ClinicalTrials.gov More Macular Edema trials